
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis Inc. is positioned favorably in the biopharmaceutical sector with a promising pipeline that includes several compounds targeting autoimmune disorders, supported by a robust precision data analytics platform. The company has projected peak sales of $2 billion for its lead candidate in systemic lupus erythematosus (SLE), with conservative estimates attributing a 20% probability of regulatory approval, indicating significant revenue potential if successful. Additionally, while no value is currently assigned to ESK-001's sales in psoriatic arthritis, the viability of this indication is bolstered by positive data from similar therapies, further enhancing Alumis's growth prospects.
Bears say
Alumis Inc faces several significant risks that contribute to a negative outlook on its stock. Key risks include the potential inability to advance its lead candidate, ESK-001, into pivotal trials in a timely manner and the possibility of failing to demonstrate compelling efficacy for targeted autoimmune conditions. Additionally, challenges such as delays in regulatory submissions, the necessity for market approvals, competitive pressures in the immunology and inflammation (I&I) space, and a slower-than-expected market uptake compound investor concerns regarding the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares